Vendor, Potomac, MD
Synergene Therapeutics Inc.
UEI W8E3G5851JK4, CAGE 43DC1
1 award and $2,280,239 obligated between February 29, 2024 and February 11, 2025, 100% under full and open competition, against 1.0 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in Biotechnology (except Nanobiotechnology)NAICS 541714 | $2,280,239 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition After Exclusion of Sources | 1 |
| Small Business Set Aside - Total | 1 |
| Definitive Contract | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| HDTRA120C0045Definitive Contract, February 29, 2024, Full and Open Competition After Exclusion of Sources, 1 offers | Defense Threat Reduction AgencyDefense Threat Reduction Agency | Application of a Nanocomplex Technology to Permeate the Blood Brain BarrierNAICS 541714, PSC AD92 | $2,280,239 |